Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2009 May;9(5):579-91. doi: 10.1517/14712590902887018 .

Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors.

Author information

  • 1Department of Hematology and VanCreveld Clinic, University Medical Center Utrecht, Utrecht, The Netherlands.

Abstract

BACKGROUND:

Adoptive transfer of T-lymphocytes is a promising treatment for a variety of malignancies, but is often not feasible due to difficulties in generating T-cells reactive with the targeted antigen from patients. To facilitate rapid generation of cells for therapy, T-cells can be programmed with genes encoding for an antigen-specific T-cell receptor (TCR) or chimeric receptors.

OBJECTIVE:

To discuss the molecular design and selected pitfalls of TCR gene modified T-cells and T-cells expressing chimeric receptors, so called T-bodies.

METHODS:

A selected review of the recent literature.

CONCLUSION:

Clinical trials report so far only limited efficacy of adoptively transferred genetically modified T-cells. However, the recent progress in engineering tumor-reactive T cells is providing a promising basis to further explore this treatment modality.

PMID:
19368527
DOI:
10.1517/14712590902887018
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center